Do spa

Quick links to important sections

Do spa

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Do spa

Quick Facts

Property Description
Active ingredient Drotaverine Hydrochloride
Form Oral tablet, Injection solution
Pharmacological class Spasmolytic Agent (Antispasmodic)
General purpose Relief of smooth muscle spasms
Origin Synthetic (benzylisoquinoline derivative)

What Type of Medicine is Do spa (Drotaverine)?

Do spa is a pharmaceutical preparation containing the active ingredient Drotaverine Hydrochloride, a synthetic compound derived from the benzylisoquinoline chemical structure. The medicine is officially classified as a Spasmolytic Agent or an antispasmodic drug due to its specific action on smooth muscles. Within the Anatomical Therapeutic Chemical (ATC) Classification system, Drotaverine is designated with the code A03AD02, placing it among drugs used for functional gastrointestinal disorders. This designation relates to the drug's use for managing functional cramping and its recognized spasmolytic effect.

Composition and Available Forms of Do spa

The core composition of Do spa is that of a single-active ingredient product, meaning the therapeutic effect relies solely on the Drotaverine Hydrochloride compound. This compound is delivered in two common dosage forms: the solid oral tablet and a sterile solution for injection. These two forms dictate the route of administration, which includes the oral route for tablets and the intramuscular or intravenous routes for the liquid solution, allowing the medication to be used in both routine management and acute settings.

What is the General Purpose of Taking a Spasmolytic Agent?

The general purpose of using Do spa is to achieve smooth muscle relaxation throughout the body's internal organs to counteract painful, involuntary tightening known as smooth muscle spasms. This is accomplished through its mechanism as a selective phosphodiesterase-4 (PDE4) inhibitor. By providing relief from this visceral spasm, such as that experienced during renal or biliary colic, the drug helps alleviate the accompanying sharp, localized pain in affected internal organs, including the gastrointestinal system and the genitourinary tract.

What side effects are possible with Do spa?

Possible Side Effects and Safety Information

The active component of this product is nicotine, and the documented safety profile reflects adverse events associated with nicotine replacement therapy. Side effects typically involve the gastrointestinal and nervous systems.

Side Effect Category Examples (Reported as Common or More Common)
Gastrointestinal Nausea, heartburn, hiccups, sore throat, mouth irritation, dyspepsia
Systemic/CNS Headache, dizziness, trouble sleeping

Serious adverse events are generally related to the cardiovascular system or signs of excessive nicotine exposure (overdose). Individuals should immediately stop use and seek medical attention if they experience symptoms such as an irregular or fast heartbeat, chest pain, or signs of nicotine overdose (including severe nausea, vomiting, dizziness, or marked weakness).

Safety Considerations

  • Cardiovascular and Pre-existing Conditions: Caution is advised, and prior consultation with a healthcare professional is necessary, for individuals with certain pre-existing conditions, including heart disease (such as a recent heart attack, irregular heartbeat, or unstable angina), uncontrolled high blood pressure, stomach ulcers, or diabetes.
  • Pregnancy and Breastfeeding: Nicotine exposure can cause harm to an unborn baby. Use during pregnancy or while breastfeeding is not recommended unless specifically directed by a healthcare provider after other methods have failed.
  • Accidental Exposure: All nicotine products must be stored securely out of the reach of children and pets, as even small amounts can cause serious toxicity or fatality in these populations. The product contains phenylalanine (aspartame) and is a consideration for individuals with phenylketonuria (PKU).

Overdose and Emergency Response

Overdose: When to Seek Help

Spironolactone overdose information is derived from official regulatory documents and focuses on managing serious electrolyte imbalances and their consequences.


Documented Overdose Manifestations

Symptoms and signs documented in regulatory sources following overdosage include:

  • Central Nervous System: Drowsiness (somnolence), mental confusion, and dizziness.
  • Gastrointestinal: Nausea, vomiting, and diarrhea.
  • Electrolyte Disturbances: Hyponatremia (low sodium) and, most critically, Hyperkalemia (high potassium).

Serious Outcomes and Emergency Action

Overdosage poses a significant risk for cardiac irregularities that may be fatal, primarily due to severe hyperkalemia. Immediate medical attention is required upon suspected overdosage. The medication should be discontinued, and the patient should seek urgent medical care or contact a poison control center.


Supportive Management

No specific antidote for spironolactone overdose has been identified. Treatment is entirely supportive and procedural, focusing on:

  • Maintaining hydration and correcting fluid and electrolyte imbalances.
  • Managing hyperkalemia through established methods.
  • Considering gastric lavage if the ingestion was recent.

Patients with impaired renal function are noted to be particularly susceptible to the severe electrolyte disturbances and related complications.

Therapeutic Uses of Do spa

What Do spa treats: Main Uses and Benefits

This treatment is used to provide supportive relief across several domains of everyday discomfort and stress-related symptoms. It is considered relevant when short-term symptomatic assistance is needed for symptoms such as mild aches, everyday physical discomfort, tension-related symptoms, and general fatigue.

Supportive care pertains to symptoms like muscle tension, stress, and pain relief, which align with the primary domains of this treatment.

This treatment may be part of symptomatic management in clinical settings that involve episodic or fluctuating symptom patterns. It is commonly used during phases when symptoms become more noticeable and create noticeable physiological strain. It may be part of symptomatic management for symptoms that interfere with daily comfort and stability, and may support general well-being during symptomatic phases. This product is relevant in contexts marked by increased discomfort or tension, which contributes to easing the overall symptom load.

Quick Fact: Relief for Tension-Related Symptoms

It is applied across domains where additional symptomatic support is needed.

Regulatory References

  1. NIH MedlinePlus overview on Non-Drug Pain Management

Eligibility and Restrictions for Use

Regulatory Eligibility Profile: Drotaverine Hydrochloride

Official regulatory documents establish strict limitations on who may and may not use Drotaverine Hydrochloride (often marketed as Do spa or No-Spa), primarily based on underlying health conditions, age, and physiological status.

Contraindicated Populations

Use is strictly prohibited for individuals diagnosed with:

  • Severe Organ Insufficiency: Severe impairment of the heart (low cardiac output syndrome), liver, or kidneys.
  • Hypersensitivity: Known allergy to drotaverine hydrochloride or any of the product's excipients.
  • Specific Metabolic Conditions: Rare hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Restricted and Conditional Use

Population Group Regulatory Status
Children under 6 years Use not established due to insufficient clinical data.
Pregnancy Avoid use unless deemed essential by a healthcare provider.
Breastfeeding/Lactation Not recommended due to a lack of data on excretion into breast milk.
Hypotension Requires special caution during use.

These official statements define non-eligibility through absolute contraindications for severe organ failure and known allergy, while establishing clear restrictions for the pediatric and perinatal populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Drotaverine focuses primarily on documented pharmacodynamic interactions and documented alterations in the absorption of co-administered medicines. The mechanistic basis for these interactions is explicitly stated in regulatory sources as pharmacodynamic reinforcement or modification of absorption/toxicity.

A critical interaction-related restriction is documented for co-administration with Levodopa, which is strongly advised against. This combination results in a severe pharmacodynamic conflict, reducing the antiparkinsonian effect of Levodopa and leading to a worsening of patient rigidity and tremor.

Drotaverine exhibits additive pharmacodynamic effects with several medicinal product categories. It enhances the action of other spasmolytic agents used for smooth muscle relaxation and intensifies the hypotensive effect when combined with drugs such as Tricyclic Antidepressants, Quinidine, or Procainamide. Conversely, Drotaverine is documented to reduce the spasmogenic activity of Morphine.

Other documented interactions relate to exposure modification. Co-administration with Magnesium Hydroxide may increase Drotaverine's absorption. Furthermore, regulatory documents note the potential for increased Lithium toxicity when these substances are taken together. No mandatory timing-based separation rules or specific population-dependent interaction considerations are explicitly stated in the reviewed official labeling.

Mechanism of Action

How Do spa Works: Biological Mechanism

The action of Drotaverine Hydrochloride is a direct myotropic effect achieved by targeting specific enzymes that regulate muscle contractility, independent of the autonomic nervous system.


Selective PDE4 Inhibition

Drotaverine acts as a selective inhibitor of the enzyme phosphodiesterase-4 ( PDE4), which is highly prevalent in the visceral smooth muscle (involuntary muscle tissue). This targeted enzymatic interaction initiates the relaxation process by blocking the breakdown of the signaling molecule cyclic AMP ( cAMP).


cAMP Cascade and Ca^2+ Modulation

The resultant increase in cAMP levels activates an intracellular signaling cascade, leading to the inactivation of MLCK (Myosin light-chain kinase) and a reduction in the availability of intracellular Ca^2+ ions. Since Ca^2+ is essential for initiating contraction, this modulation of the cAMP- Ca^2+ pathway directly reduces the smooth muscle's ability to sustain contraction, resulting in a decrease in muscle tone. The mechanism is constrained to visceral muscle and does not modulate physiological processes related to non-spasmodic nociception.

Dosage and Administration Information

How to Use Do spa: Official Administration Guidelines

Do spa (Drotaverine Hydrochloride) is administered via the oral route as a tablet and via the intramuscular (IM) or intravenous (IV) routes as a solution. These instructions determine the appropriate dose and method of delivery.


Standard Dosage and Administration

Instruction Detail
Route of Administration Oral, Intramuscular, or Intravenous.
Adult Oral Dosing The recommended daily dose is 120 mg to 240 mg. The maximum daily limit is 240 mg.
Dosing Frequency The total daily oral dose must be divided and taken in 2 to 3 separate doses.
Acute Parenteral Use For acute episodes, such as colics, a single dose of 40 mg to 80 mg may be administered intravenously (IV).
Administration Timing Oral tablets may be taken with or without food.

Special Procedural and Population Rules

Parenteral Administration: The injection solution is administered by a healthcare professional. Intravenous administration requires the dose to be given slowly and is typically reserved for acute, severe episodes.

Pediatric Dosing: Standard labeling provides specific dosage limitations for younger patients:

  • Children 6 to 12 years: The maximum daily oral dose is 80 mg, administered in 2 separate doses.
  • Children over 12 years: The maximum daily oral dose is 160 mg, administered in 2 to 4 separate doses.

Organ Impairment: Documentation imposes constraints on use in patients with severe hepatic or renal insufficiency, which dictates required dose adjustments or exclusion from use.

These instructions define the standardized protocol for using the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Drotaverine (Do spa)


Evidence for Use in Managing Functional Gastrointestinal Spasms (IBS)

Research has explored the medicine relevant in trials assessing short-term or episodic symptom patterns related to Irritable Bowel Syndrome (IBS) in adults. Studies were primarily conducted as short-term Randomized Controlled Trials (RCTs). These trials monitored and measured patient-reported outcomes describing perceived discomfort, specifically focusing on changes in abdominal pain severity and the frequency of pain episodes.

Studies reported measurements related to changes in short-term pain scores over observed periods. The research highlights changes measured during the study period, contributing to understanding how patients reported their experience of functional spasms. However, the evidence is limited and heterogeneous. Long-term effects are not fully established, and follow-up durations were limited, typically lasting only two to four weeks. As a result, there is limited information for long-term outcomes regarding symptom patterns for chronic conditions.


Evidence for Use in Acute Visceral Pain (Renal Colic)

Drotaverine was evaluated in studies conducted in acute care settings for patients presenting with sudden, severe pain, such as that caused by kidney or ureteric stones, known as renal colic. Research examined the medicine's use alongside or in comparison to standard pain assessment options. The studies monitored outcomes describing episodic or acute changes, specifically measuring the immediate change in pain intensity and the necessity for subsequent rescue pain medication.

Research described patterns related to rapid, short-term changes in pain intensity following administration. Reports documented patterns in the requirement for additional analgesia following the initial dose. The reported outcomes are specific to the urgent assessment of pain in the acute care environment. Research is concentrated only on the urgent, acute phase of the condition. Evidence provides limited insight into outcomes for the condition beyond acute symptom assessment.


Evidence in Pediatric and Other Special Populations

Research has explored the use of Drotaverine in specific populations, notably in school-age children with a diagnosis of Recurrent Abdominal Pain (RAP). These studies monitored outcomes related to systemic or functional imbalance, such as the frequency of pain episodes and their reported intensity.

However, the data for certain groups remain insufficient. The research for RAP in children is derived from a limited number of trials, which contributes to the current scope of the evidence base. Consequently, the long-term effects are not fully established for children, and the certainty remains low due to the scarcity of high-quality, large-scale studies.

Key Studies & References

  1. Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome - A Network Meta-Analysis
  2. Comparison of the Efficacy and Tolerability of Drotaverine 80 mg, Ibuprofen 400 mg and Their Combination in Primary and Secondary Dysmenorrhoea (Trial NCT00292747)

Frequently Asked Questions (FAQ)

Common questions about Do spa (FAQ)

Q: How quickly should I expect to feel relief after taking Do spa?

A: Regulatory data indicates that the active ingredient typically reaches its highest measurable concentration in the bloodstream approximately one to three hours after oral administration. Some clinical reports suggest that patients have noticed a positive change in spasm-related pain within the first hour of taking the medicine.


Q: What are the most commonly reported side effects of Do spa?

A: Official product information lists possible side effects, which are generally reported as rare. These may include nausea, constipation, headaches, dizziness, palpitations, and episodes of low blood pressure (hypotension).


Q: Can I use Do spa if I am breastfeeding/lactating?

A: Official regulatory guidance generally states that the use of this medicine is not recommended during breastfeeding. This is due to a lack of sufficient data on whether the active substance is excreted into breast milk.


Q: Is it true that Do spa can sometimes cause low blood pressure?

A: Official regulatory documents list hypotension (low blood pressure) as a possible, though uncommon, side effect of the medicine. The product label also indicates that special caution is required for use in patients who already experience low blood pressure.


Q: Is it common to feel a little dizzy or lightheaded when first starting Do spa?

A: Official product information notes that dizziness (vertigo) is a possible side effect, though it is not frequently reported. The regulatory text advises that dizziness, if experienced, can potentially impair the ability to operate machinery or drive.


Q: What research evidence supports the use of Do spa for its intended treatments?

A: Clinical trials have been conducted to assess the medicine's effect on conditions like Irritable Bowel Syndrome (IBS) and acute pain episodes such as renal colic (kidney stones). The available research has evaluated the medicine for short-term relief of pain and discomfort, particularly in conditions involving smooth muscle spasms.


Q: Is Do spa the same as Drotaverine or is it a different formulation?

A: The medicine branded as Do spa contains the active substance Drotaverine Hydrochloride. Multiple brands containing this same active ingredient may be available in different regions.


Q: Can Do spa cause drowsiness, making it unsafe to drive?

A: Sedation or strong central nervous system effects are not commonly reported with this medicine. However, because possible side effects such as dizziness have been noted, caution is advised regarding driving or operating machinery if these effects occur.


Q: Are there any specific foods or drinks I should avoid while on Do spa?

A: Regulatory information indicates that the oral tablets may be taken with or without food. There are no commonly known interactions or specific warnings regarding the avoidance of common food items or non-alcoholic drinks while taking this medicine.


Q: How long does Do spa stay in your system after you stop taking it?

A: Pharmacokinetic data suggests that the half-life—the time it takes for half of the substance to be eliminated from the body—is typically between seven and twelve hours.


Q: Are there specific symptoms that signal an allergic reaction to Do spa?

A: Hypersensitivity is a known contraindication for this medicine. Reported signs of a severe reaction may include rash, joint pain, or swelling of the face, lips, or tongue. Any signs of a severe allergic reaction necessitate immediate medical assistance.


Q: Can Do spa affect my sleep patterns or cause insomnia?

A: Official product information lists insomnia, or difficulty sleeping, as one of the possible side effects that may be associated with the use of this medicine.


Q: Is Do spa effective for muscle spasms not related to internal organs (skeletal muscle spasms)?

A: The medicine’s mechanism of action is selective for visceral smooth muscle (the involuntary muscle of internal organs). Because its mechanism is selective for visceral smooth muscle, it does not typically affect skeletal (voluntary) muscle.


Q: Is Do spa ever used for menstrual cramps?

A: Yes, due to its action on smooth muscle spasms, the medicine is often indicated or prescribed for the symptomatic relief of pain associated with painful menstruation (dysmenorrhea).


Q: Can Do spa be taken by people with a history of heart conditions?

A: The medicine is strictly contraindicated (prohibited) for those with severe heart conditions, such as low cardiac output syndrome. For individuals with a history of non-severe heart conditions, regulatory documents indicate that the medicine should be used with caution.


Q: Is there a generic version of Do spa available, and is it as effective?

A: The active substance in the medicine is the generic compound Drotaverine Hydrochloride. This generic substance is available under various brand names, and pharmaceutically equivalent versions are generally available in many regions.


Q: Does Do spa have any known impact on liver or kidney function?

A: The medicine is strictly contraindicated in patients who have been diagnosed with severe hepatic (liver) or severe renal (kidney) insufficiency. In cases of less severe impairment, regulatory documents state that caution is required.


Q: Is it normal to experience constipation as a side effect of Do spa?

A: Official product information lists constipation as one of the possible gastrointestinal side effects that may occur, although side effects are generally reported as rare.


Q: Is Do spa safe for use during pregnancy?

A: Official guidance recommends that use during pregnancy should be avoided. It is typically only to be used when a healthcare provider deems it absolutely essential due to the limited human data on its safety for the unborn baby.

How should Do spa be stored and disposed of?

How to Store and Dispose of Do spa (Drotaverine Hydrochloride)

Official regulatory documents define specific conditions for storing and disposing of this medicine to maintain its quality and ensure safety.


Storage Requirements

Storage Parameter Regulatory Requirement
Temperature Do not store above 30 C.
Protection Must be protected from light and moisture; store in a dry place.
Packaging Keep in the original container/outer carton and keep the container tightly closed.
Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Do spa must not be disposed of via wastewater or household waste. Disposal should be carried out strictly in accordance with local requirements for pharmaceutical waste, which often involves returning the product to a pharmacy or authorized collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Do spa found in:

A-Z Index: